Treatment With Granulocyte ColonyeCStimulating Factor Prevents Diabetes in NOD Mice by Recruiting Plasmacytoid Dendritic Cells and Functiona
http://www.100md.com
糖尿病学杂志 2005年第1期
1 National Institute of Health and Medical Research, INSERM U580, Necker Enfants Malades Research Institute, Hpital Necker, Paris, France
2 Pathology Laboratory, Bichat-Claude Bernard Hospital, Assistance Publique Hpitaux de Paris, Paris, France
ABSTRACT
Accumulating evidence that granulocyte colonyeCstimulating factor (G-CSF), the key hematopoietic growth factor of the myeloid lineage, not only represents a major component of the endogenous response to infections, but also affects adaptive immune responses, prompted us to investigate the therapeutic potential of G-CSF in autoimmune type 1 diabetes. Treatment with G-CSF protected NOD mice from developing spontaneous diabetes. G-CSF triggered marked recruitment of dendritic cells (DCs), particularly immature CD11cloB220+ plasmacytoid DCs, with reduced costimulatory signal expression and higher interferon- but lower interleukin-12p70 release capacity than DCs in excipient-treated mice. G-CSF recipients further displayed accumulation of functional CD4+CD25+ regulatory T-cells that produce transforming growth factor-1 (TGF-1) and actively suppressed diabetes transfer by diabetogenic effector cells in secondary NOD-SCID recipients. G-CSF’s ability to promote key tolerogenic interactions between DCs and regulatory T-cells was demonstrated by enhanced recruitment of TGF-1eCexpressing CD4+CD25+ cells after adoptive transfer of DCs isolated from G-CSFeC relative to vehicle-treated mice into naive NOD recipients. The present results suggest that G-CSF, a promoter of tolerogenic DCs, may be evaluated for the treatment of human type 1 diabetes, possibly in association with direct inhibitors of T-cell activation. They also provide a rationale for a protective role of the endogenous G-CSF produced during infections in early diabetes.
There is compelling evidence that granulocyte colonyeCstimulating factor (G-CSF), well known as the hematopoietic growth factor of the myeloid lineage (1) and a major response factor to infections (2), also exerts profound immunoregulatory influence in adaptive immunity. In patients treated with G-CSF, T-cell allogeneic and mitogenic reactivities are inhibited (3), corresponding to a reduced interferon (IFN)- production capacity (4) and a cytokine response skewed toward TH2 (5). Recipients of G-CSFeCmobilized peripheral blood stem cells do not display a higher incidence of graft-versus-host disease (GVHD) than bone marrow recipients, despite the larger numbers of T-cells in unmanipulated stem cell grafts (6). In experimental models, G-CSF was shown to protect mice from GVHD by orienting the T-cell response to TH2 (7). Moreover, G-CSF was protective in experimental endotoxemia by inhibiting the inflammatory response, particularly production of tumor necrosis factor- (8). More recently, G-CSF was reported to induce the emergence of tolerogenic dendritic cells (DCs) (i.e., pro-DC2) (9,10), as well as Tr1-like regulatory T-cells (11) in the peripheral blood of normal human recipients, thus promoting the expansion of potentially tolerogenic subsets at both poles of the antigen-presenting cell (APC)/T-cell interaction. We therefore investigated whether G-CSF, a particularly well-tolerated molecule, might also be used to promote tolerance in pathophysiological settings such as autoimmune diseases.
We recently showed that G-CSF, at 200 e · kgeC1 · dayeC1, exhibits therapeutic potential in two different models of autoimmune diseases: systemic lupus (12), a spontaneous systemic disease characterized by immune complex deposits leading to lethal glomerulonephritis, and experimental autoimmune encephalomyelitis (EAE) (13), a T-celleCmediated demyelinating disease actively induced by immunization with myelin antigens. G-CSF has also been shown to be expressed within central nervous system lesions at the acute phase of multiple sclerosis (14), thus suggesting an endogenous role for this hematopoietic growth factor in the control of autoreactive processes. We now present evidence that G-CSF treatment prevents another T-celleCmediated disease, spontaneous autoimmune type 1 diabetes, in the NOD mouse. This protection correlated with marked recruitment of CD11cloB220+ plasmacytoid DCs (pDCs), an immature tolerogenic DC subset that in turn recruits CD4+CD25+ regulatory T-cells, which exhibit suppressive properties in secondary recipients.
RESEARCH DESIGN AND METHODS
NOD/Thy1.2 (Kd, I-Ag7, Db) mice were bred in our animal facilities under specific pathogen-free conditions. Female NOD mice (n = 12 mice per group) received five consecutive daily subcutaneous injections of recombinant human G-CSF (Neupogen; Amgen; 200 e · kgeC1 · dayeC1), which is active in mice (7), at ages 4, 8, 12, and 16 weeks. The excipient consisted of 5% dextrose in sterile H2O. Colorimetric strips were used to monitor glycosuria twice a week (Glukotest; Boehringer-Mannheim, Mannheim, Germany) and glycemia (Hemoglukotest and Reflolux F; Boehringer-Mannheim). Mice with blood glucose levels >250 mg/dl on two consecutive readings were considered diabetic. All animal experiments were conducted according to the regulations of the French Agricultural Ministry.
Pancreata were removed, embedded in Tissue-Tek OCT (optimal cutting temperature) (Sakura, Zoeterwoude, the Netherlands), and snap-frozen in liquid nitrogen. For conventional histopathology, serial 2-e sections were stained with hematoxylin and eosin to score mononuclear cell infiltration as follows: grade 0 = normal islets; grade 1 = focal or peripheral insulitis (lymphocytes gathered at a pole or surrounding the islet, but no destruction of endocrine cells as assessed by labeling with anti-insulin antibodies); and grade 2 = invasive destructive insulitis.
Antibodies and fluorescence-activated cell sorter analysis.
Spleen and pancreatic lymph node (PLN) cell content was analyzed at age 20 weeks. For DC analyses, spleens and PLN cells were digested with collagenase (1 mg/ml) and DNAse (40 e/ml), after which single-cell suspensions were prepared. CD4+ and CD11c+ cells (90 and 60eC85% pure, respectively, confirmed by fluorescence-activated cell sorter [FACS] analysis) were positively enriched with antieCCD4- and antieCCD11c-labeled immunomagnetic cell sorting (MACS) microbeads (Miltenyi Biotec, Paris, France), respectively.
The cell surface phenotype of PLN cells, splenocytes, and isolated cell subsets was analyzed by flow cytometry. All cells were incubated in cold PBS supplemented with 2% FCS and 0.02% azide. Cells were preincubated in 20 e蘬 for 15 min at room temperature, under constant shaking, with anti-Fc receptor II/III (clone 2.4G2) to reduce nonspecific binding, followed by the monoclonal antibodies anti-CD4 (clone GK1.5), anti-CD25 (clone 7D4), anti-CD3 (clone 145eC2C11), anti-B220 (clone RA3eC6B2), anti-CD11c (clone HL3), anti-CD80 (B7eC1; clone 16eC10A1), anti-CD86 (B7eC2; clone GL-1), anti-CD40 (clone 3/23), anti-IA/IE (clone M5/114.15.2), and antieCMac-1/CD11b (clone M1/70). These were purchased from PharMingen (Becton Dickinson, Le Pont de Claix, France) and were used coupled with biotin and revealed by streptavidin-APC (PharMingen), or with phycoerythrin (PE) or fluorescein isothiocyanate (FITC). Using the FACScalibur flow cytometer (Becton Dickinson), 10,000 events were acquired. Analyses of the acquired data were performed using CellQuest software (Becton Dickinson).
Expression of costimulatory molecules and cytokine production by DCs.
CD11c+ cells were enriched from spleen with MACS immunobeads (Miltenyi Biotec) and cultivated (2 x 105 cells · welleC1 · 0.2 mleC1) in 96-well plates over 24 h in RPMI 1640 medium supplemented with 5% FCS. Cells were then collected, and the expression of the major histocompatibility complex (MHC) class II and costimulatory molecules CD80, CD86, and CD40 was analyzed by FACS, as described above. Their spontaneous release of cytokines was measured in supernatants with a specific enzyme-linked immunosorbent assay for interleukin (IL)-12p70 and IFN- (R&D Systems Europe, Lille, France).
FACS analysis of cytokine expression.
Membrane expression of transforming growth factor-1 (TGF-1) was measured on gated CD4+CD25+ cells, freshly isolated from PLN or spleen, labeled with FITC-coupled antieCTGF-1 antibody (clone 2G7; prepared from hybridoma in our laboratory), or IgG2b isotype control antibody. Intracytoplasmic expression of TGF-1 and interleukin (IL)-10, IFN-, and IL-4 was assessed after a 5-h stimulation of PLN cells isolated from primary G-CSF and excipient recipients with phorbol myristic acid (PMA; 10 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A during the last 2 h (2 e/ml). This was followed by permeabilization with saponin and subsequent staining with specific antibodies, including PE-labeled antieCIL-10 (clone JES5-16E3; Becton Dickinson), allophycocyanin-labeled antieCIL-4 (clone 11B11; Becton Dickinson), FITC-coupled antieCTGF-1, or PE-coupled antieCIFN- (clone XMG1.2; Becton Dickinson), and corresponding IgG1 or IgG2b isotype control antibodies. Results were analyzed on a FACScalibur cytometer (Becton Dickinson) using CellQuest software for total PLN cells and gated CD4+ cells.
Isolation of CD25+ and CD25eC cells from spleen and PLN of G-CSFeCprotected recipients and cotransfer into NOD-SCID mice together with diabetogenic splenocytes.
Spleen and PLN cells were collected from G-CSF recipients, depleted of B220+ cells using rat anti-mouse B220 and anti-rat coated Dynabeads (Dynal, Compieegne, France), and subsequently magnetically sorted into CD25+ and CD25eC cells using biotinylated anti-CD25 antibody and streptavidin-coated magnetic beads (Miltenyi Biotech). Either total splenocytes (107 cells) or the different sorted cell subsets from spleen (106 CD25+ cells) and PLN (106 CD25eC cells or 2.5 x 105 CD25+ cells) were subsequently injected into 4-week-old NOD-SCID recipients (n = 6 mice per group) together with 3 x 106 splenocytes from a recently diabetic NOD mouse. The diabetes incidence in these groups was then compared with that in a group of mice injected with only 3 x 106 splenocytes from a recently diabetic NOD mouse.
Isolation of CD11c+ DCs from PLN of G-CSFeC and excipient-treated NOD mice and transfer into secondary NOD recipients.
Female NOD mice, age 4 weeks, were injected over 5 consecutive days with 200 e/kg G-CSF or excipient (n = 5 per group). On day 10, spleen CD11c+ cells were isolated with immunomagnetic microbeads (Miltenyi Biotec) and successively transferred intravenously (4 x 105 cells/100 e蘬) into the secondary recipients, 4-week-old female NOD mice. Then 7 days later, the percent of CD4+CD25+ cells within the spleen of secondary recipients (n = 3 per group) was assessed by FACS analysis.
Statistical analysis.
Student’s t test was used to determine the statistical significance of differences among groups. The occurrence of diabetes in the different experimental groups was plotted using the Kaplan-Meier method (i.e., nonparametric cumulated survival plot). The statistical comparison was performed using the log-rank (Mantel-Cox) test, which provided the corresponding 2 values.
RESULTS
G-CSF treatment prevents spontaneous diabetes and insulitis.
NOD (Thy1.2) female mice, age 4 weeks, received subcutaneous treatment with recombinant human G-CSF (200 e · kgeC1 · dayeC1) or vehicle over 5 consecutive days; this protocol was repeated every 4 weeks thereafter (i.e., at ages 4, 8, 12, and 16 weeks). Recipients of G-CSF were significantly protected from diabetes (P = 0.002, 2 test) (Fig. 1A). At age 25 weeks, vehicle-injected mice presented with advanced destruction of pancreatic islets (with very few remaining islets, heavily infiltrated, grade 2), whereas numerous pancreatic islets remained in G-CSFeCprotected mice, of which 70% showed peripheral and/or focal insulitis (grade 1) and 30% showed invasive insulitis (grade 2) (Fig. 1B). Insulitis scores remained essentially unchanged in the G-CSFeCtreated mice examined at age 30 weeks (n = 3; data not shown), and the animals remained disease free.
Accumulation of immature DCs in G-CSFeCtreated mice.
Several lines of evidence support the notion that an imbalance exists in NOD mice favoring immunogenic versus tolerogenic DCs, thereby predisposing NOD mice to autoimmune diabetes development (15eC19). It is important to note that G-CSF has been shown to promote the development of specific tolerogenic DC subsets in human subjects (10). We therefore analyzed DC phenotype and maturation status in vehicle- and G-CSFeCtreated NOD mice. Spleen CD11c+ percentages were significantly increased in G-CSFeC relative to vehicle-treated mice (4.8 ± 0.7 vs. 2.7 ± 0.4% of total spleen cells; data not shown), which, combined with the relative spleen enlargement due to the hematopoietic properties of G-CSF (77 ± 10 vs. 48 ± 4.2 x 106 cells in vehicle-treated mice), corresponded to a 2.8-fold enrichment in DC numbers per spleen. G-CSF had no effect on the relative percent of myeloid CD11c+CD11b+ DCs (data not shown). Conversely, 15 ± 1% CD11c+ cells in G-CSF recipients expressed the CD11cloB220+ phenotype, which has been reported to correspond to pDCs with tolerogenic properties (20,21), compared with 8.8 ± 0.5% of CD11c+ cells in vehicle-treated mice (Fig. 2A), representing a 5.4-fold enrichment in pDC numbers per mouse spleen (5.55 vs. 1.03 x 105 pDCs per spleen). Moreover, CD11c+ DCs from G-CSFeCtreated mice displayed characteristics of immature DCs, with lower levels of expression of the MHC II complex and the costimulatory molecule CD80, but not CD86 or CD40 (Fig. 2B), than DCs from vehicle-treated mice.
DCs from G-CSFeC or excipient-treated mice further displayed a distinct spontaneous cytokine production pattern, as measured in supernatants after 24-h incubation in culture medium. Thus, in keeping with their enrichment in CD11cloB220+ pDCs, CD11c+ cells enriched from G-CSFeCtreated mice spontaneously released in their supernatants more IFN-, but much less IL-12 p70, than CD11c+ cells from excipient-treated diabetic mice (Fig. 2C).
G-CSF enhances CD4+CD25+ T-cell subset.
Given the properties of pDCs to expand regulatory T-cells (22,23), we next analyzed whether this significant increase in pDC number in G-CSF recipients correlated with enhanced accumulation or preservation of the tolerogenic T-cell subset. Indeed, an imbalance between diabetogenic effectors and the immunoregulatory T-cell subset expressing the CD4+CD25+ phenotype is observed as spontaneous diabetes develops in the NOD mouse (24). Diabetogenic effectors leave the PLN to invade the pancreatic islets, as the regulatory T-cell pool declines with age and loses suppressive potential (25). In 20-week-old mice, the size of the CD4+CD25+ cell subset in the PLN was notably enhanced (3.5-fold) after G-CSF treatment (0.497 ± 0.06 [G-CSFeCtreated mice] vs. 0.141 ± 0.015 [excipient-treated mice] vs. 0.28 ± 0.03 [untreated 6-week-old NOD mice] x 106 cells) (Fig. 3A). We observed a 50% less increase in CD4+CD25+ cell numbers (1.76 fold) in spleen cells in G-CSFeC vs. excipient-treated mice (3.18 ± 0.35 vs. 1.8 ± 0.15 x 106 cells) (Fig. 3A).
CD4+CD25+ cells in PLN of G-CSF recipients express membrane-bound and secreted TGF-1.
To examine the functional properties of the CD4+CD25+ cells accumulating in G-CSF recipients, spontaneous membrane expression of TGF-1 (26,27) was measured on nonpermeabilized PLN cells. Half of gated CD4+CD25+ cells expressed high and intermediate levels of the suppressive cytokine in 20-week-old G-CSF recipients relative to only 34% of CD4+CD25+ cells in age-matched, excipient-treated NOD mice (Fig. 3B) and naive 6-week-old NOD mice.
The cytokine production pattern was also analyzed by FACS after PMA and ionomycin activation (Fig. 3C). In both groups of mice, 30% of PLN cells and 50% of CD4+ cells within this compartment expressed intracellular TGF-1, but levels of expression were remarkably higher in G-CSFeC relative to excipient-treated mice. IL-10 production was observed in only 1.5% of PLN CD4+ cells (0.8% total PLN cells) in G-CSF recipients, all of which produce high levels of TGF-1 (data not shown). Conversely, only 2.7% of CD4+ PLN cells produced IFN- after PMA and ionomycin activation in G-CSF recipients, relative to 5.3% in vehicle-treated mice; IL-4 was undetectable.
Adoptively transferred CD25+ cells isolated from PLN, but not from spleen of G-CSF-treated mice, protect secondary NOD-SCID recipients against diabetogenic effectors.
To assess the in vivo suppressive properties of T-cells accumulating in G-CSFeCprotected NOD mice, we magnetically sorted CD25+ and CD25eC populations from the PLN and spleen of these protected recipients and cotransferred them into secondary NOD-SCID recipients together with 3 x 106 splenocytes from recently diabetic NOD mice (Fig. 4). Only CD25+ (with as few as 2.5 x 105 cells), but not CD25eC (1 x 106 cells) PLN-derived cells, significantly delayed diabetes onset in these recipients (P = 0.002, 2 test), whereas the spleen-derived CD25+ (1 x 106 cells) subset was unable to provide significant protection against diabetes. Therefore, the protective effect of G-CSF treatment was mediated by recruitment of CD4+CD25+ cells selectively within the PLN; those cells remained functional and actively suppressed the diabetogenic effect of autoreactive effector cells in cotransfer experiments in NOD-SCID recipients.
DCs from G-CSF recipients effectively recruit regulatory T-cells.
To assess the primary target of G-CSF and fully understand the interaction between immature DCs and regulatory T-cells that accumulate in G-CSF recipients, 4-week-old NOD mice were treated with G-CSF or excipient over 5 consecutive days. On day 10, isolated spleen CD11c+ cells (70eC85% pure), including 18.2% CD11cloB220+ cells in G-CSF recipients relative to 5.3% in vehicle recipients (not shown), were subsequently transferred (4 x 105 cells) into secondary 4-week-old NOD recipients; the percent of CD4+CD25+ T-cells in recipient mice was analyzed 7 days later. In keeping with their relative enrichment in pDCs (which have the potential to recruit regulatory T-cells), adoptively transferred DCs from G-CSF recipients led to threefold increased proportions of CD4+CD25+ cells in the spleen of the recipients relative to DCs isolated from vehicle-treated mice (Fig. 5A). An important finding was that CD4+CD25+ cells accumulating in the recipients of DCs from G-CSFeCtreated mice expressed significantly higher levels of membrane-bound TGF-1 (Fig. 5B). A more limited (1.2-fold) CD4+CD25+ cell enrichment was also observed at days 7 and 20 in peripancreatic and mesenteric lymph nodes of DC recipients (not shown), in keeping with the splenic origin of the transferred DCs and the intravenous route of injection used. Thus, G-CSF promoted key tolerogenic interactions between DCs and regulatory T-cells.
DISCUSSION
G-CSF treatment administered to NOD mice over 5 consecutive days every 4 weeks starting from age 4 weeks provided significant protection against spontaneous diabetes, a T-celleCmediated autoimmune disease. This protection correlated with marked recruitment of two major regulatory subsets, pDCs and regulatory CD4+CD25+ T-cells.
The possibility that G-CSF has a direct effect on T-cells cannot be eliminated, as the presence of G-CSF receptors on minor subsets of the T-cell lineage, yet to be identified, has been recently reported (10,28,29). However an effect via cells of the myeloid lineage is more likely, as the presence of G-CSF receptors is widely recognized on these cells (1,2) and we have previously shown that G-CSF was able to switch macrophages to a pro-Th2 chemokine balance in mice undergoing EAE (13). An imbalance favoring immunogenic rather than tolerogenic DCs is suspected to contribute to diabetes development in the NOD mouse. Reported DC abnormalities in NOD mice include increased proportions of a myeloid DC (CD11c+CD11b+) subset within the spleen relative to diabetes-resistant, recombinant, congenic NOR mice (15), as well as elevated costimulatory properties through the increased percent of CD80- and CD86-expressing CD11c+ cells and increased expression of these molecules during T-cell stimulation (15,16). NOD DCs are also characterized by persistent hyperactivation of nuclear factor-B, which is responsible for coordinated upregulation of MHC expression, costimulation of molecules, and cytokine synthesis (18,19). It is remarkable that G-CSF has been shown to favor accumulation of pro-DC2 in human subjects and human recipients of G-CSFeCmobilized peripheral blood mononuclear cells (9). We therefore examined the effect of G-CSF treatment on DC subsets in the NOD mouse. CD11c+ cells were significantly increased in spleen of G-CSF NOD recipients. Although no significant difference was found in the relative proportions of myeloid CD11c+CD11b+ DCs, G-CSF recipients displayed enhanced proportions of the CD11cloB220+ dendritic subtype, a phenotype attributed to tolerogenic pDCs, that were accordingly characterized with high IFN- (20,30) but low IL-12p70 production capacity. In addition, they displayed features of immature DCs, with a lower expression of the MHC II complex and the costimulatory molecule CD80. It is important that specific tolerogenic or immature pDC subsets have been shown to exert a major influence on regulatory T-cell accumulation (22,31). Indeed, when CD11c+ DCs isolated from the spleen of mice treated for 5 days with G-CSF, which were enriched in CD11cloB220+ cells relative to excipient-treated mice, were transferred into secondary naive NOD recipients, they triggered recruitment of CD4+CD25+ cells at a higher level than did CD11c+ cells enriched from excipient-treated mice. This confirmed a primary role of DCs in the specific accumulation of the regulatory CD4+CD25+ T-cell subset observed in G-CSF recipients relative to excipient-treated mice.
That CD4+CD25+ T-cells accumulating in G-CSF recipients presented functional suppressive properties was demonstrated 1) ex vivo by FACS analysis, showing their capacity to produce the immunosuppressive cytokine TGF-1 at the membrane and intracellular levels (26,27) and 2) in vivo by their protective properties in cotransfer experiments against diabetogenic effectors in secondary NOD-SCID recipients. These observations concur with recent reports of regulatory T-cells accumulating in peripheral blood of human G-CSF recipients (11). However, in human subjects, IL-10eCproducing Tr1-like regulatory T-cells have been described, at variance with the CD4+CD25+ cells we observed in NOD mouse PLN that produced low levels of IL-10 but high levels of TGF-1. It is noteworthy that when isolated, only the CD25+ cell fraction from PLN cells in these G-CSF recipients exerted active suppression in vivo, with as few as 2.5 x 105 of these cells significantly delaying diabetes transfer by 3 x 106 diabetogenic splenocytes in cotransfer experiments in NOD-SCID recipients. Because immunization with autoantigen(s) has been demonstrated to take place within the draining lymph nodes of the target tissue, the more pronounced enrichment of these functional regulatory T-cells within PLN supports the notion that the cellular mechanisms accounting for G-CSF’s protective effects are specifically targeted at the autoreactive response. Moreover, the present data also confirm that CD4+CD25+ regulatory T-cells from PLN display a much higher protective efficiency against diabetes than CD4+CD25+ cells from spleen or other peripheral lymph nodes (32). The present data obtained in the NOD mouse model show that G-CSF administration durably preserves the pool of functional regulatory T-cells by resetting the critical DC balance toward tolerance.
Given that G-CSF’s capacity to promote in vivo expansion of immature DCs as well as functional regulatory T-cells has also been reported in humans (9,10,33,34), this hematopoietic growth factor may have therapeutic potential in human subjects with autoimmune diseases. Indeed, treatment with the clinically well-tolerated G-CSF may represent a safer and less invasive therapeutic strategy than cell therapy with bone marroweCderived DCs. However, the therapeutic window for intervention with DCs or tolerogenic DC-inducing agents such as G-CSF remains to be ascertained. Thus far, DCs have been shown to protect NOD mice from diabetes when transferred at age 5eC6 weeks (35eC37). Their influence at later disease stages has not yet been reported. An exacerbation of autoimmune diseases, particularly neurological manifestations of lupus and multiple sclerosis, has been reported in patients with end-stage autoimmune disease who were treated with G-CSF in the course of mobilizing hematopoietic stem cells for clinical trials of autologous stem cell transplantation (38). These aggravating effects of G-CSF were abrogated when G-CSF was administered together with cyclophosphamide or high-dosage corticosteroids. We could not observe any effect, either deleterious or protective, of G-CSF on diabetes incidence in the NOD mouse when treatment was started later in the disease (age 9 weeks; data not shown). One possible interpretation of these findings is that the early infiltration of islets by immunogenic DCs, which occurs at age 3eC7 weeks and onwards in the NOD mouse (39) and initiates (subsequent autoimmune islet injury) may actually define a checkpoint for immunointervention with tolerogenic DC subsets as with G-CSF. Given the role of DCs to T-cell interaction in the control of immune tolerance, the possibility that a synergistic combination of G-CSF, as a DC maturation inhibitor, with T-celleCactivation inhibitors such as the CD3 antibody (40,41), might prove useful in patients at risk for developing type 1 diabetes (42) warrants further investigation.
Our results may also shed some light on the possible role that infectious events that trigger endogenous production of G-CSF can play on the development of autoimmune diabetes and more generally on molecular mechanisms involved in the control of adaptive immunity by innate immunity. Indeed, there is compelling evidence that infections may influence diabetes frequency in human populations (43). Vaccination with mycobacteria products such as complete Freund adjuvant (44) can prevent the onset of type 1 diabetes in the NOD mouse. Recent reports suggest that not only might protection be achieved by mycobacterial components such as hsp65 (45), but also that endogenous response factors to infections, such as G-CSF, could be involved. For example, mycobacterial infection of IFN-eC/eC mice is characterized by enhanced extramedullar hematopoiesis and the presence of high levels of G-CSF in the serum of these mice in conjunction with IL-6. These observations have disclosed a critical balance in innate immunity between IFN- and G-CSF (46). Our present results demonstrate that this molecular balance may also influence the onset of autoimmune diseases and suggest that stimulation of an endogenous production of G-CSF by infections at an early phase of autoimmune diabetes may prevent disease.
In conclusion, our results disclose that G-CSF, an essential mediator in innate immune responses, may also contribute to the control of adaptive immunity and, as was shown here, particularly of autoimmune type 1 diabetes. Patients’ remarkable tolerance for G-CSF, which has been used in clinics for >10 years, should prompt the therapeutic evaluation of this molecule in autoimmune diseases.
ACKNOWLEDGMENTS
This work was supported by funds from INSERM and the Juvenile Diabetes Research Foundation. H.K. is the recipient of an INSERMeCReegion Ile de France fellowship. F.Z. is an investigator at Centre National de la Recherche Scientifique. G-CSF (Neupogen) was a kind gift of Amgen, France.
FOOTNOTES
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
APC, antigen-presenting cell; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; FACS, fluorescence-activated cell sorter; FITC, fluorescein isothiocyanate; G-CSF, granulocyte colonyeCstimulating factor; GVHD, graft-versus-host disease; IFN, interferon; IL, interleukin; MACS, magnetic cell sorting; MHC, major histocompatibility complex; pDC, plasmacytoid dendritic cell; PE, phycoerythrin; PLN, pancreatic lymph node; PMA, phorbol myristic acid; TGF-1, transforming growth factor-1
REFERENCES
Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (r-metHuG-CSF): the first 10 years. Blood88 :1907 eC1929,1996
Basu S, Dunn A, Ward A: G-CSF: function and modes of action (Review). Int J Mol Med10 :3 eC10,2002
Mielcarek M, Martin PJ, Torok-Storb B: Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood89 :1629 eC1634,1997
Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood85 :2482 eC2489,1995
Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood95 :2269 eC2274,2000
Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood85 :1659 eC1665,1995
Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood86 :4422 eC4429,1995
Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol149 :918 eC924,1992
Reddy V: Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation. Blood96 :2635 ,2000
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C: Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood95 :2484 eC2490,2000
Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d’Onofrio G, Leone G: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood100 :2562 eC2571,2002
Zavala F, Masson A, Hadaya K, Ezine S, Schneider E, Babin O, Bach JF: Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol163 :5125 eC5132,1999
Zavala F, Abad S, Ezine S, Taupin V, Masson A, Bach JF: G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol168 :2011 eC2019,2002
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med8 :500 eC508,2002
Steptoe RJ, Ritchie JM, Harrison LC: Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J Immunol168 :5032 eC5041,2002
Marleau AM, Singh B: Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J Autoimmun19 :23 eC35,2002
Feili-Hariri M, Morel PA: Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin Immunol98 :133 eC142,2001
Weaver DJ Jr, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS Jr, Tisch R: Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol167 :1461 eC1468,2001
Poligone B, Weaver DJ Jr, Sen P, Baldwin AS Jr, Tisch R: Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol168 :188 eC196,2002
Nakano H, Yanagita M, Gunn MD: CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med194 :1171 eC1178,2001
Bjorck P: The multifaceted murine plasmacytoid dendritic cell. Hum Immunol63 :1094 eC1102,2002
Moser M: Dendritic cells in immunity and tolerance: do they display opposite functions Immunity19 :5 eC8,2003
Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol21 :685 eC711,2003
Bach JF, Chatenoud L: Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol19 :131 eC161,2001
Gregori S, Giarratana N, Smiroldo S, Adorini L: Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol171 :4040 eC4047,2003
Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol172 :834 eC842,2004
Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med194 :629 eC644,2001
Morikawa K, Morikawa S, Nakamura M, Miyawaki T: Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Br J Haematol118 :296 eC304,2002
Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, Schmitt-Thomsen A, Hertenstein B, Buer J, Ganser A: G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood102 :734 eC739,2003
O’Keeffe M, Hochrein H, Vremec D, Caminschi I, Miller JL, Anders EM, Wu L, Lahoud MH, Henri S, Scott B, Hertzog P, Tatarczuch L, Shortman K: Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med196 :1307 eC1319,2002
Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A99 :351 eC358,2002
Green EA, Choi Y, Flavell RA: Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity16 :183 eC191,2002
Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol165 :566 eC572,2000
Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, Ferrara JL: G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation69 :691 eC693,2000
Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA: Immunotherapy of NOD mice with bone marroweCderived dendritic cells. Diabetes48 :2300 eC2308,1999
Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S: Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Clin Exp Immunol134 :388 eC395,2003
Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C: Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest90 :741 eC748,1992
Burt RK, Slavin S, Burns WH, Marmont AM: Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure Blood99 :768 eC784,2002
Rosmalen JG, Leenen PJ, Pelegri C, Drexhage HA, Homo-Delarche F: Islet abnormalities in the pathogenesis of autoimmune diabetes. Trends Endocrinol Metab13 :209 eC214,2002
Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A91 :123 eC127,1994
Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med9 :1202 eC1208,2003
Gottlieb PA, Eisenbarth GS: Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med49 :391 eC405,1998
Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med347 :911 eC920,2002
Sadelain MW, Qin HY, Lauzon J, Singh B: Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes39 :583 eC589,1990
Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR: Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A88 :3088 eC3091,1991
Murray PJ, Young RA, Daley GQ: Hematopoietic remodeling in interferon-gamma-deficient mice infected with mycobacteria. Blood91 :2914 eC2924,1998(Hassen Kared, Annie Masso)
2 Pathology Laboratory, Bichat-Claude Bernard Hospital, Assistance Publique Hpitaux de Paris, Paris, France
ABSTRACT
Accumulating evidence that granulocyte colonyeCstimulating factor (G-CSF), the key hematopoietic growth factor of the myeloid lineage, not only represents a major component of the endogenous response to infections, but also affects adaptive immune responses, prompted us to investigate the therapeutic potential of G-CSF in autoimmune type 1 diabetes. Treatment with G-CSF protected NOD mice from developing spontaneous diabetes. G-CSF triggered marked recruitment of dendritic cells (DCs), particularly immature CD11cloB220+ plasmacytoid DCs, with reduced costimulatory signal expression and higher interferon- but lower interleukin-12p70 release capacity than DCs in excipient-treated mice. G-CSF recipients further displayed accumulation of functional CD4+CD25+ regulatory T-cells that produce transforming growth factor-1 (TGF-1) and actively suppressed diabetes transfer by diabetogenic effector cells in secondary NOD-SCID recipients. G-CSF’s ability to promote key tolerogenic interactions between DCs and regulatory T-cells was demonstrated by enhanced recruitment of TGF-1eCexpressing CD4+CD25+ cells after adoptive transfer of DCs isolated from G-CSFeC relative to vehicle-treated mice into naive NOD recipients. The present results suggest that G-CSF, a promoter of tolerogenic DCs, may be evaluated for the treatment of human type 1 diabetes, possibly in association with direct inhibitors of T-cell activation. They also provide a rationale for a protective role of the endogenous G-CSF produced during infections in early diabetes.
There is compelling evidence that granulocyte colonyeCstimulating factor (G-CSF), well known as the hematopoietic growth factor of the myeloid lineage (1) and a major response factor to infections (2), also exerts profound immunoregulatory influence in adaptive immunity. In patients treated with G-CSF, T-cell allogeneic and mitogenic reactivities are inhibited (3), corresponding to a reduced interferon (IFN)- production capacity (4) and a cytokine response skewed toward TH2 (5). Recipients of G-CSFeCmobilized peripheral blood stem cells do not display a higher incidence of graft-versus-host disease (GVHD) than bone marrow recipients, despite the larger numbers of T-cells in unmanipulated stem cell grafts (6). In experimental models, G-CSF was shown to protect mice from GVHD by orienting the T-cell response to TH2 (7). Moreover, G-CSF was protective in experimental endotoxemia by inhibiting the inflammatory response, particularly production of tumor necrosis factor- (8). More recently, G-CSF was reported to induce the emergence of tolerogenic dendritic cells (DCs) (i.e., pro-DC2) (9,10), as well as Tr1-like regulatory T-cells (11) in the peripheral blood of normal human recipients, thus promoting the expansion of potentially tolerogenic subsets at both poles of the antigen-presenting cell (APC)/T-cell interaction. We therefore investigated whether G-CSF, a particularly well-tolerated molecule, might also be used to promote tolerance in pathophysiological settings such as autoimmune diseases.
We recently showed that G-CSF, at 200 e · kgeC1 · dayeC1, exhibits therapeutic potential in two different models of autoimmune diseases: systemic lupus (12), a spontaneous systemic disease characterized by immune complex deposits leading to lethal glomerulonephritis, and experimental autoimmune encephalomyelitis (EAE) (13), a T-celleCmediated demyelinating disease actively induced by immunization with myelin antigens. G-CSF has also been shown to be expressed within central nervous system lesions at the acute phase of multiple sclerosis (14), thus suggesting an endogenous role for this hematopoietic growth factor in the control of autoreactive processes. We now present evidence that G-CSF treatment prevents another T-celleCmediated disease, spontaneous autoimmune type 1 diabetes, in the NOD mouse. This protection correlated with marked recruitment of CD11cloB220+ plasmacytoid DCs (pDCs), an immature tolerogenic DC subset that in turn recruits CD4+CD25+ regulatory T-cells, which exhibit suppressive properties in secondary recipients.
RESEARCH DESIGN AND METHODS
NOD/Thy1.2 (Kd, I-Ag7, Db) mice were bred in our animal facilities under specific pathogen-free conditions. Female NOD mice (n = 12 mice per group) received five consecutive daily subcutaneous injections of recombinant human G-CSF (Neupogen; Amgen; 200 e · kgeC1 · dayeC1), which is active in mice (7), at ages 4, 8, 12, and 16 weeks. The excipient consisted of 5% dextrose in sterile H2O. Colorimetric strips were used to monitor glycosuria twice a week (Glukotest; Boehringer-Mannheim, Mannheim, Germany) and glycemia (Hemoglukotest and Reflolux F; Boehringer-Mannheim). Mice with blood glucose levels >250 mg/dl on two consecutive readings were considered diabetic. All animal experiments were conducted according to the regulations of the French Agricultural Ministry.
Pancreata were removed, embedded in Tissue-Tek OCT (optimal cutting temperature) (Sakura, Zoeterwoude, the Netherlands), and snap-frozen in liquid nitrogen. For conventional histopathology, serial 2-e sections were stained with hematoxylin and eosin to score mononuclear cell infiltration as follows: grade 0 = normal islets; grade 1 = focal or peripheral insulitis (lymphocytes gathered at a pole or surrounding the islet, but no destruction of endocrine cells as assessed by labeling with anti-insulin antibodies); and grade 2 = invasive destructive insulitis.
Antibodies and fluorescence-activated cell sorter analysis.
Spleen and pancreatic lymph node (PLN) cell content was analyzed at age 20 weeks. For DC analyses, spleens and PLN cells were digested with collagenase (1 mg/ml) and DNAse (40 e/ml), after which single-cell suspensions were prepared. CD4+ and CD11c+ cells (90 and 60eC85% pure, respectively, confirmed by fluorescence-activated cell sorter [FACS] analysis) were positively enriched with antieCCD4- and antieCCD11c-labeled immunomagnetic cell sorting (MACS) microbeads (Miltenyi Biotec, Paris, France), respectively.
The cell surface phenotype of PLN cells, splenocytes, and isolated cell subsets was analyzed by flow cytometry. All cells were incubated in cold PBS supplemented with 2% FCS and 0.02% azide. Cells were preincubated in 20 e蘬 for 15 min at room temperature, under constant shaking, with anti-Fc receptor II/III (clone 2.4G2) to reduce nonspecific binding, followed by the monoclonal antibodies anti-CD4 (clone GK1.5), anti-CD25 (clone 7D4), anti-CD3 (clone 145eC2C11), anti-B220 (clone RA3eC6B2), anti-CD11c (clone HL3), anti-CD80 (B7eC1; clone 16eC10A1), anti-CD86 (B7eC2; clone GL-1), anti-CD40 (clone 3/23), anti-IA/IE (clone M5/114.15.2), and antieCMac-1/CD11b (clone M1/70). These were purchased from PharMingen (Becton Dickinson, Le Pont de Claix, France) and were used coupled with biotin and revealed by streptavidin-APC (PharMingen), or with phycoerythrin (PE) or fluorescein isothiocyanate (FITC). Using the FACScalibur flow cytometer (Becton Dickinson), 10,000 events were acquired. Analyses of the acquired data were performed using CellQuest software (Becton Dickinson).
Expression of costimulatory molecules and cytokine production by DCs.
CD11c+ cells were enriched from spleen with MACS immunobeads (Miltenyi Biotec) and cultivated (2 x 105 cells · welleC1 · 0.2 mleC1) in 96-well plates over 24 h in RPMI 1640 medium supplemented with 5% FCS. Cells were then collected, and the expression of the major histocompatibility complex (MHC) class II and costimulatory molecules CD80, CD86, and CD40 was analyzed by FACS, as described above. Their spontaneous release of cytokines was measured in supernatants with a specific enzyme-linked immunosorbent assay for interleukin (IL)-12p70 and IFN- (R&D Systems Europe, Lille, France).
FACS analysis of cytokine expression.
Membrane expression of transforming growth factor-1 (TGF-1) was measured on gated CD4+CD25+ cells, freshly isolated from PLN or spleen, labeled with FITC-coupled antieCTGF-1 antibody (clone 2G7; prepared from hybridoma in our laboratory), or IgG2b isotype control antibody. Intracytoplasmic expression of TGF-1 and interleukin (IL)-10, IFN-, and IL-4 was assessed after a 5-h stimulation of PLN cells isolated from primary G-CSF and excipient recipients with phorbol myristic acid (PMA; 10 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A during the last 2 h (2 e/ml). This was followed by permeabilization with saponin and subsequent staining with specific antibodies, including PE-labeled antieCIL-10 (clone JES5-16E3; Becton Dickinson), allophycocyanin-labeled antieCIL-4 (clone 11B11; Becton Dickinson), FITC-coupled antieCTGF-1, or PE-coupled antieCIFN- (clone XMG1.2; Becton Dickinson), and corresponding IgG1 or IgG2b isotype control antibodies. Results were analyzed on a FACScalibur cytometer (Becton Dickinson) using CellQuest software for total PLN cells and gated CD4+ cells.
Isolation of CD25+ and CD25eC cells from spleen and PLN of G-CSFeCprotected recipients and cotransfer into NOD-SCID mice together with diabetogenic splenocytes.
Spleen and PLN cells were collected from G-CSF recipients, depleted of B220+ cells using rat anti-mouse B220 and anti-rat coated Dynabeads (Dynal, Compieegne, France), and subsequently magnetically sorted into CD25+ and CD25eC cells using biotinylated anti-CD25 antibody and streptavidin-coated magnetic beads (Miltenyi Biotech). Either total splenocytes (107 cells) or the different sorted cell subsets from spleen (106 CD25+ cells) and PLN (106 CD25eC cells or 2.5 x 105 CD25+ cells) were subsequently injected into 4-week-old NOD-SCID recipients (n = 6 mice per group) together with 3 x 106 splenocytes from a recently diabetic NOD mouse. The diabetes incidence in these groups was then compared with that in a group of mice injected with only 3 x 106 splenocytes from a recently diabetic NOD mouse.
Isolation of CD11c+ DCs from PLN of G-CSFeC and excipient-treated NOD mice and transfer into secondary NOD recipients.
Female NOD mice, age 4 weeks, were injected over 5 consecutive days with 200 e/kg G-CSF or excipient (n = 5 per group). On day 10, spleen CD11c+ cells were isolated with immunomagnetic microbeads (Miltenyi Biotec) and successively transferred intravenously (4 x 105 cells/100 e蘬) into the secondary recipients, 4-week-old female NOD mice. Then 7 days later, the percent of CD4+CD25+ cells within the spleen of secondary recipients (n = 3 per group) was assessed by FACS analysis.
Statistical analysis.
Student’s t test was used to determine the statistical significance of differences among groups. The occurrence of diabetes in the different experimental groups was plotted using the Kaplan-Meier method (i.e., nonparametric cumulated survival plot). The statistical comparison was performed using the log-rank (Mantel-Cox) test, which provided the corresponding 2 values.
RESULTS
G-CSF treatment prevents spontaneous diabetes and insulitis.
NOD (Thy1.2) female mice, age 4 weeks, received subcutaneous treatment with recombinant human G-CSF (200 e · kgeC1 · dayeC1) or vehicle over 5 consecutive days; this protocol was repeated every 4 weeks thereafter (i.e., at ages 4, 8, 12, and 16 weeks). Recipients of G-CSF were significantly protected from diabetes (P = 0.002, 2 test) (Fig. 1A). At age 25 weeks, vehicle-injected mice presented with advanced destruction of pancreatic islets (with very few remaining islets, heavily infiltrated, grade 2), whereas numerous pancreatic islets remained in G-CSFeCprotected mice, of which 70% showed peripheral and/or focal insulitis (grade 1) and 30% showed invasive insulitis (grade 2) (Fig. 1B). Insulitis scores remained essentially unchanged in the G-CSFeCtreated mice examined at age 30 weeks (n = 3; data not shown), and the animals remained disease free.
Accumulation of immature DCs in G-CSFeCtreated mice.
Several lines of evidence support the notion that an imbalance exists in NOD mice favoring immunogenic versus tolerogenic DCs, thereby predisposing NOD mice to autoimmune diabetes development (15eC19). It is important to note that G-CSF has been shown to promote the development of specific tolerogenic DC subsets in human subjects (10). We therefore analyzed DC phenotype and maturation status in vehicle- and G-CSFeCtreated NOD mice. Spleen CD11c+ percentages were significantly increased in G-CSFeC relative to vehicle-treated mice (4.8 ± 0.7 vs. 2.7 ± 0.4% of total spleen cells; data not shown), which, combined with the relative spleen enlargement due to the hematopoietic properties of G-CSF (77 ± 10 vs. 48 ± 4.2 x 106 cells in vehicle-treated mice), corresponded to a 2.8-fold enrichment in DC numbers per spleen. G-CSF had no effect on the relative percent of myeloid CD11c+CD11b+ DCs (data not shown). Conversely, 15 ± 1% CD11c+ cells in G-CSF recipients expressed the CD11cloB220+ phenotype, which has been reported to correspond to pDCs with tolerogenic properties (20,21), compared with 8.8 ± 0.5% of CD11c+ cells in vehicle-treated mice (Fig. 2A), representing a 5.4-fold enrichment in pDC numbers per mouse spleen (5.55 vs. 1.03 x 105 pDCs per spleen). Moreover, CD11c+ DCs from G-CSFeCtreated mice displayed characteristics of immature DCs, with lower levels of expression of the MHC II complex and the costimulatory molecule CD80, but not CD86 or CD40 (Fig. 2B), than DCs from vehicle-treated mice.
DCs from G-CSFeC or excipient-treated mice further displayed a distinct spontaneous cytokine production pattern, as measured in supernatants after 24-h incubation in culture medium. Thus, in keeping with their enrichment in CD11cloB220+ pDCs, CD11c+ cells enriched from G-CSFeCtreated mice spontaneously released in their supernatants more IFN-, but much less IL-12 p70, than CD11c+ cells from excipient-treated diabetic mice (Fig. 2C).
G-CSF enhances CD4+CD25+ T-cell subset.
Given the properties of pDCs to expand regulatory T-cells (22,23), we next analyzed whether this significant increase in pDC number in G-CSF recipients correlated with enhanced accumulation or preservation of the tolerogenic T-cell subset. Indeed, an imbalance between diabetogenic effectors and the immunoregulatory T-cell subset expressing the CD4+CD25+ phenotype is observed as spontaneous diabetes develops in the NOD mouse (24). Diabetogenic effectors leave the PLN to invade the pancreatic islets, as the regulatory T-cell pool declines with age and loses suppressive potential (25). In 20-week-old mice, the size of the CD4+CD25+ cell subset in the PLN was notably enhanced (3.5-fold) after G-CSF treatment (0.497 ± 0.06 [G-CSFeCtreated mice] vs. 0.141 ± 0.015 [excipient-treated mice] vs. 0.28 ± 0.03 [untreated 6-week-old NOD mice] x 106 cells) (Fig. 3A). We observed a 50% less increase in CD4+CD25+ cell numbers (1.76 fold) in spleen cells in G-CSFeC vs. excipient-treated mice (3.18 ± 0.35 vs. 1.8 ± 0.15 x 106 cells) (Fig. 3A).
CD4+CD25+ cells in PLN of G-CSF recipients express membrane-bound and secreted TGF-1.
To examine the functional properties of the CD4+CD25+ cells accumulating in G-CSF recipients, spontaneous membrane expression of TGF-1 (26,27) was measured on nonpermeabilized PLN cells. Half of gated CD4+CD25+ cells expressed high and intermediate levels of the suppressive cytokine in 20-week-old G-CSF recipients relative to only 34% of CD4+CD25+ cells in age-matched, excipient-treated NOD mice (Fig. 3B) and naive 6-week-old NOD mice.
The cytokine production pattern was also analyzed by FACS after PMA and ionomycin activation (Fig. 3C). In both groups of mice, 30% of PLN cells and 50% of CD4+ cells within this compartment expressed intracellular TGF-1, but levels of expression were remarkably higher in G-CSFeC relative to excipient-treated mice. IL-10 production was observed in only 1.5% of PLN CD4+ cells (0.8% total PLN cells) in G-CSF recipients, all of which produce high levels of TGF-1 (data not shown). Conversely, only 2.7% of CD4+ PLN cells produced IFN- after PMA and ionomycin activation in G-CSF recipients, relative to 5.3% in vehicle-treated mice; IL-4 was undetectable.
Adoptively transferred CD25+ cells isolated from PLN, but not from spleen of G-CSF-treated mice, protect secondary NOD-SCID recipients against diabetogenic effectors.
To assess the in vivo suppressive properties of T-cells accumulating in G-CSFeCprotected NOD mice, we magnetically sorted CD25+ and CD25eC populations from the PLN and spleen of these protected recipients and cotransferred them into secondary NOD-SCID recipients together with 3 x 106 splenocytes from recently diabetic NOD mice (Fig. 4). Only CD25+ (with as few as 2.5 x 105 cells), but not CD25eC (1 x 106 cells) PLN-derived cells, significantly delayed diabetes onset in these recipients (P = 0.002, 2 test), whereas the spleen-derived CD25+ (1 x 106 cells) subset was unable to provide significant protection against diabetes. Therefore, the protective effect of G-CSF treatment was mediated by recruitment of CD4+CD25+ cells selectively within the PLN; those cells remained functional and actively suppressed the diabetogenic effect of autoreactive effector cells in cotransfer experiments in NOD-SCID recipients.
DCs from G-CSF recipients effectively recruit regulatory T-cells.
To assess the primary target of G-CSF and fully understand the interaction between immature DCs and regulatory T-cells that accumulate in G-CSF recipients, 4-week-old NOD mice were treated with G-CSF or excipient over 5 consecutive days. On day 10, isolated spleen CD11c+ cells (70eC85% pure), including 18.2% CD11cloB220+ cells in G-CSF recipients relative to 5.3% in vehicle recipients (not shown), were subsequently transferred (4 x 105 cells) into secondary 4-week-old NOD recipients; the percent of CD4+CD25+ T-cells in recipient mice was analyzed 7 days later. In keeping with their relative enrichment in pDCs (which have the potential to recruit regulatory T-cells), adoptively transferred DCs from G-CSF recipients led to threefold increased proportions of CD4+CD25+ cells in the spleen of the recipients relative to DCs isolated from vehicle-treated mice (Fig. 5A). An important finding was that CD4+CD25+ cells accumulating in the recipients of DCs from G-CSFeCtreated mice expressed significantly higher levels of membrane-bound TGF-1 (Fig. 5B). A more limited (1.2-fold) CD4+CD25+ cell enrichment was also observed at days 7 and 20 in peripancreatic and mesenteric lymph nodes of DC recipients (not shown), in keeping with the splenic origin of the transferred DCs and the intravenous route of injection used. Thus, G-CSF promoted key tolerogenic interactions between DCs and regulatory T-cells.
DISCUSSION
G-CSF treatment administered to NOD mice over 5 consecutive days every 4 weeks starting from age 4 weeks provided significant protection against spontaneous diabetes, a T-celleCmediated autoimmune disease. This protection correlated with marked recruitment of two major regulatory subsets, pDCs and regulatory CD4+CD25+ T-cells.
The possibility that G-CSF has a direct effect on T-cells cannot be eliminated, as the presence of G-CSF receptors on minor subsets of the T-cell lineage, yet to be identified, has been recently reported (10,28,29). However an effect via cells of the myeloid lineage is more likely, as the presence of G-CSF receptors is widely recognized on these cells (1,2) and we have previously shown that G-CSF was able to switch macrophages to a pro-Th2 chemokine balance in mice undergoing EAE (13). An imbalance favoring immunogenic rather than tolerogenic DCs is suspected to contribute to diabetes development in the NOD mouse. Reported DC abnormalities in NOD mice include increased proportions of a myeloid DC (CD11c+CD11b+) subset within the spleen relative to diabetes-resistant, recombinant, congenic NOR mice (15), as well as elevated costimulatory properties through the increased percent of CD80- and CD86-expressing CD11c+ cells and increased expression of these molecules during T-cell stimulation (15,16). NOD DCs are also characterized by persistent hyperactivation of nuclear factor-B, which is responsible for coordinated upregulation of MHC expression, costimulation of molecules, and cytokine synthesis (18,19). It is remarkable that G-CSF has been shown to favor accumulation of pro-DC2 in human subjects and human recipients of G-CSFeCmobilized peripheral blood mononuclear cells (9). We therefore examined the effect of G-CSF treatment on DC subsets in the NOD mouse. CD11c+ cells were significantly increased in spleen of G-CSF NOD recipients. Although no significant difference was found in the relative proportions of myeloid CD11c+CD11b+ DCs, G-CSF recipients displayed enhanced proportions of the CD11cloB220+ dendritic subtype, a phenotype attributed to tolerogenic pDCs, that were accordingly characterized with high IFN- (20,30) but low IL-12p70 production capacity. In addition, they displayed features of immature DCs, with a lower expression of the MHC II complex and the costimulatory molecule CD80. It is important that specific tolerogenic or immature pDC subsets have been shown to exert a major influence on regulatory T-cell accumulation (22,31). Indeed, when CD11c+ DCs isolated from the spleen of mice treated for 5 days with G-CSF, which were enriched in CD11cloB220+ cells relative to excipient-treated mice, were transferred into secondary naive NOD recipients, they triggered recruitment of CD4+CD25+ cells at a higher level than did CD11c+ cells enriched from excipient-treated mice. This confirmed a primary role of DCs in the specific accumulation of the regulatory CD4+CD25+ T-cell subset observed in G-CSF recipients relative to excipient-treated mice.
That CD4+CD25+ T-cells accumulating in G-CSF recipients presented functional suppressive properties was demonstrated 1) ex vivo by FACS analysis, showing their capacity to produce the immunosuppressive cytokine TGF-1 at the membrane and intracellular levels (26,27) and 2) in vivo by their protective properties in cotransfer experiments against diabetogenic effectors in secondary NOD-SCID recipients. These observations concur with recent reports of regulatory T-cells accumulating in peripheral blood of human G-CSF recipients (11). However, in human subjects, IL-10eCproducing Tr1-like regulatory T-cells have been described, at variance with the CD4+CD25+ cells we observed in NOD mouse PLN that produced low levels of IL-10 but high levels of TGF-1. It is noteworthy that when isolated, only the CD25+ cell fraction from PLN cells in these G-CSF recipients exerted active suppression in vivo, with as few as 2.5 x 105 of these cells significantly delaying diabetes transfer by 3 x 106 diabetogenic splenocytes in cotransfer experiments in NOD-SCID recipients. Because immunization with autoantigen(s) has been demonstrated to take place within the draining lymph nodes of the target tissue, the more pronounced enrichment of these functional regulatory T-cells within PLN supports the notion that the cellular mechanisms accounting for G-CSF’s protective effects are specifically targeted at the autoreactive response. Moreover, the present data also confirm that CD4+CD25+ regulatory T-cells from PLN display a much higher protective efficiency against diabetes than CD4+CD25+ cells from spleen or other peripheral lymph nodes (32). The present data obtained in the NOD mouse model show that G-CSF administration durably preserves the pool of functional regulatory T-cells by resetting the critical DC balance toward tolerance.
Given that G-CSF’s capacity to promote in vivo expansion of immature DCs as well as functional regulatory T-cells has also been reported in humans (9,10,33,34), this hematopoietic growth factor may have therapeutic potential in human subjects with autoimmune diseases. Indeed, treatment with the clinically well-tolerated G-CSF may represent a safer and less invasive therapeutic strategy than cell therapy with bone marroweCderived DCs. However, the therapeutic window for intervention with DCs or tolerogenic DC-inducing agents such as G-CSF remains to be ascertained. Thus far, DCs have been shown to protect NOD mice from diabetes when transferred at age 5eC6 weeks (35eC37). Their influence at later disease stages has not yet been reported. An exacerbation of autoimmune diseases, particularly neurological manifestations of lupus and multiple sclerosis, has been reported in patients with end-stage autoimmune disease who were treated with G-CSF in the course of mobilizing hematopoietic stem cells for clinical trials of autologous stem cell transplantation (38). These aggravating effects of G-CSF were abrogated when G-CSF was administered together with cyclophosphamide or high-dosage corticosteroids. We could not observe any effect, either deleterious or protective, of G-CSF on diabetes incidence in the NOD mouse when treatment was started later in the disease (age 9 weeks; data not shown). One possible interpretation of these findings is that the early infiltration of islets by immunogenic DCs, which occurs at age 3eC7 weeks and onwards in the NOD mouse (39) and initiates (subsequent autoimmune islet injury) may actually define a checkpoint for immunointervention with tolerogenic DC subsets as with G-CSF. Given the role of DCs to T-cell interaction in the control of immune tolerance, the possibility that a synergistic combination of G-CSF, as a DC maturation inhibitor, with T-celleCactivation inhibitors such as the CD3 antibody (40,41), might prove useful in patients at risk for developing type 1 diabetes (42) warrants further investigation.
Our results may also shed some light on the possible role that infectious events that trigger endogenous production of G-CSF can play on the development of autoimmune diabetes and more generally on molecular mechanisms involved in the control of adaptive immunity by innate immunity. Indeed, there is compelling evidence that infections may influence diabetes frequency in human populations (43). Vaccination with mycobacteria products such as complete Freund adjuvant (44) can prevent the onset of type 1 diabetes in the NOD mouse. Recent reports suggest that not only might protection be achieved by mycobacterial components such as hsp65 (45), but also that endogenous response factors to infections, such as G-CSF, could be involved. For example, mycobacterial infection of IFN-eC/eC mice is characterized by enhanced extramedullar hematopoiesis and the presence of high levels of G-CSF in the serum of these mice in conjunction with IL-6. These observations have disclosed a critical balance in innate immunity between IFN- and G-CSF (46). Our present results demonstrate that this molecular balance may also influence the onset of autoimmune diseases and suggest that stimulation of an endogenous production of G-CSF by infections at an early phase of autoimmune diabetes may prevent disease.
In conclusion, our results disclose that G-CSF, an essential mediator in innate immune responses, may also contribute to the control of adaptive immunity and, as was shown here, particularly of autoimmune type 1 diabetes. Patients’ remarkable tolerance for G-CSF, which has been used in clinics for >10 years, should prompt the therapeutic evaluation of this molecule in autoimmune diseases.
ACKNOWLEDGMENTS
This work was supported by funds from INSERM and the Juvenile Diabetes Research Foundation. H.K. is the recipient of an INSERMeCReegion Ile de France fellowship. F.Z. is an investigator at Centre National de la Recherche Scientifique. G-CSF (Neupogen) was a kind gift of Amgen, France.
FOOTNOTES
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
APC, antigen-presenting cell; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; FACS, fluorescence-activated cell sorter; FITC, fluorescein isothiocyanate; G-CSF, granulocyte colonyeCstimulating factor; GVHD, graft-versus-host disease; IFN, interferon; IL, interleukin; MACS, magnetic cell sorting; MHC, major histocompatibility complex; pDC, plasmacytoid dendritic cell; PE, phycoerythrin; PLN, pancreatic lymph node; PMA, phorbol myristic acid; TGF-1, transforming growth factor-1
REFERENCES
Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (r-metHuG-CSF): the first 10 years. Blood88 :1907 eC1929,1996
Basu S, Dunn A, Ward A: G-CSF: function and modes of action (Review). Int J Mol Med10 :3 eC10,2002
Mielcarek M, Martin PJ, Torok-Storb B: Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood89 :1629 eC1634,1997
Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood85 :2482 eC2489,1995
Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood95 :2269 eC2274,2000
Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood85 :1659 eC1665,1995
Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood86 :4422 eC4429,1995
Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol149 :918 eC924,1992
Reddy V: Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation. Blood96 :2635 ,2000
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C: Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood95 :2484 eC2490,2000
Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d’Onofrio G, Leone G: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood100 :2562 eC2571,2002
Zavala F, Masson A, Hadaya K, Ezine S, Schneider E, Babin O, Bach JF: Granulocyte-colony stimulating factor treatment of lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol163 :5125 eC5132,1999
Zavala F, Abad S, Ezine S, Taupin V, Masson A, Bach JF: G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J Immunol168 :2011 eC2019,2002
Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med8 :500 eC508,2002
Steptoe RJ, Ritchie JM, Harrison LC: Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J Immunol168 :5032 eC5041,2002
Marleau AM, Singh B: Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J Autoimmun19 :23 eC35,2002
Feili-Hariri M, Morel PA: Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin Immunol98 :133 eC142,2001
Weaver DJ Jr, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS Jr, Tisch R: Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol167 :1461 eC1468,2001
Poligone B, Weaver DJ Jr, Sen P, Baldwin AS Jr, Tisch R: Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol168 :188 eC196,2002
Nakano H, Yanagita M, Gunn MD: CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med194 :1171 eC1178,2001
Bjorck P: The multifaceted murine plasmacytoid dendritic cell. Hum Immunol63 :1094 eC1102,2002
Moser M: Dendritic cells in immunity and tolerance: do they display opposite functions Immunity19 :5 eC8,2003
Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol21 :685 eC711,2003
Bach JF, Chatenoud L: Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol19 :131 eC161,2001
Gregori S, Giarratana N, Smiroldo S, Adorini L: Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol171 :4040 eC4047,2003
Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol172 :834 eC842,2004
Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med194 :629 eC644,2001
Morikawa K, Morikawa S, Nakamura M, Miyawaki T: Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Br J Haematol118 :296 eC304,2002
Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, Schmitt-Thomsen A, Hertenstein B, Buer J, Ganser A: G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood102 :734 eC739,2003
O’Keeffe M, Hochrein H, Vremec D, Caminschi I, Miller JL, Anders EM, Wu L, Lahoud MH, Henri S, Scott B, Hertzog P, Tatarczuch L, Shortman K: Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med196 :1307 eC1319,2002
Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A99 :351 eC358,2002
Green EA, Choi Y, Flavell RA: Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity16 :183 eC191,2002
Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol165 :566 eC572,2000
Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, Ferrara JL: G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation69 :691 eC693,2000
Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA: Immunotherapy of NOD mice with bone marroweCderived dendritic cells. Diabetes48 :2300 eC2308,1999
Morin J, Faideau B, Gagnerault MC, Lepault F, Boitard C, Boudaly S: Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice. Clin Exp Immunol134 :388 eC395,2003
Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C: Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest90 :741 eC748,1992
Burt RK, Slavin S, Burns WH, Marmont AM: Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure Blood99 :768 eC784,2002
Rosmalen JG, Leenen PJ, Pelegri C, Drexhage HA, Homo-Delarche F: Islet abnormalities in the pathogenesis of autoimmune diabetes. Trends Endocrinol Metab13 :209 eC214,2002
Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A91 :123 eC127,1994
Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med9 :1202 eC1208,2003
Gottlieb PA, Eisenbarth GS: Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med49 :391 eC405,1998
Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med347 :911 eC920,2002
Sadelain MW, Qin HY, Lauzon J, Singh B: Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes39 :583 eC589,1990
Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR: Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A88 :3088 eC3091,1991
Murray PJ, Young RA, Daley GQ: Hematopoietic remodeling in interferon-gamma-deficient mice infected with mycobacteria. Blood91 :2914 eC2924,1998(Hassen Kared, Annie Masso)